大成生化科技(00809.HK)開始供應商債務重組安排
格隆匯6月9日丨大成生化科技(00809.HK)公吿，為促成供應商債務重組安排，相關供應商近期已專為供應商債務重組安排設立供應商中國合夥企業。所有供應商中國合夥企業均以相同方式設立，因此所有相關供應商參照集團結欠彼等的應付款項金額享有供應商債務重組安排項下的同等權利。
於2025年6月9日，(i)各供應商中國合夥企業(作為初始債權人及認購人)；(ii)世紀大成(作為債務人及發行人)；(iii)公司全資附屬公司及世紀大成直接股東大成生化科技集團有限公司("大成香港")訂立各份債轉股協議。根據債轉股協議，各供應商中國合夥企業將動用各供應商債務金額(合共人民幣461.1百萬元)認購世紀大成新增註冊資本，於完成後，該等資本應視為已繳足註冊資本，合共佔世紀大成約28.98%股權。
債轉股協議完成須待集團取得所有監管同意及授權，包括但不限於商務部主管部門所要求的批准或備案後，方吿作實。債轉股協議完成後，世紀大成將由供應商中國合夥企業合共持有約28.98%，及由大成香港持有約71.02%。世紀大成將仍為公司附屬公司。債轉股協議已包含禁售條款，據此供應商中國合夥企業所持世紀大成任何股權僅可為供應商債務重組安排目的而持有，不得出售、用作擔保、質押、設置產權負擔或以任何其他方式處置。
為解決供應商債務，供應商中國有限合夥所持世紀大成的股權最終將置換為本公司上市股份。根據債轉股協議的規定，供應商中國有限合夥應於香港設立有限公司形式的特殊目的工具("供應商特殊目的工具")，並將其各自於世紀大成的股權轉讓予其各自的供應商特殊目的工具。作為供應商債務重組安排的最後一步，公司將透過發行公司新股份作為代價股份，向供應商特殊目的工具收購世紀大成合共約28.98%股權，即供應商特殊目的工具所持世紀大成的全部股權。該代價(即供應商債務於扣除折讓後的金額)尚未於債轉股協議內協定。
根據最新磋商，預期該折讓幅度不會低於30.0%。剔除供應商債務折讓金額與作為代價股份發行的公司新股份的公允值差額影響，預期集團將就該供應商債務折讓錄得淨收益不少於約190.0百萬港元。於本公吿日期，集團與供應商中國有限合夥或其任何代名人並無就發行公司股份訂立具法律約束力的協議，亦未就發行價格達成共識。
於上述股權置換完成後，世紀大成將再次成為公司的間接全資附屬公司。因此，世紀大成的最終實益擁有權不會變動，且於緊接供應商債務重組安排完成前及緊隨供應商債務重組安排完成後亦不會對集團於世紀大成的權益造成整體影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
